TuHURA Biosciences, Inc./NV
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
HURA$1.66+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $2,697,416 | $12,657,178 |
| Deposits, planned business acquisition (note 1) | - | 5,994,503 |
| Other current assets | 806,429 | 958,708 |
| Total Current Assets | 3,503,845 | 19,610,389 |
| Property and equipment, net | 295,332 | 123,366 |
| Operating right-of-use assets | 82,707 | 199,160 |
| Other noncurrent assets | - | 33,769 |
| Goodwill | 13,554,164 | - |
| In-process research and development | 8,261,000 | - |
| Total Assets | $25,697,048 | $19,966,684 |
| Liabilities and Stockholders' Equity | ||
| Current Liabilities: | ||
| Accounts payable and accrued expenses | $5,480,577 | $5,170,166 |
| Note Payable to former Kineta employees | 493,386 | - |
| Holdback liability, payable in shares | 2,775,795 | - |
| Lease liabilities, current | 84,346 | 159,844 |
| Total Current Liabilities | 8,834,104 | 5,330,010 |
| Long-term Liabilities: | ||
| Lease liability, long term | - | 42,698 |
| Other long-term liabilities | 84,985 | - |
| Total Liabilities | 8,919,089 | 5,372,708 |
| Stockholders' Equity: | ||
| Preferred Stock Series A (assumed in Kintara merger); $1.00 par value, 278,530 shares outstanding as of September 30, 2025 and December 31, 2024 | 278,530 | 278,530 |
| Common stock, $0.001 par value, 200,000,000 and 75,000,000 shares authorized; 51,254,789 and 42,323,759 shares issued and outstanding as of September 30, 2025 and December 31, 2024. | 51,255 | 42,324 |
| Additional paid in capital | 150,869,671 | 125,397,691 |
| Accumulated deficit | (134,421,497) | (111,124,569) |
| Total Stockholders’ Equity | 16,777,959 | 14,593,976 |
| Total Liabilities and Stockholders' Equity | $25,697,048 | $19,966,684 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.